SOLVD Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991 Aug 1;325(5):293-302.
AIRE Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993 Oct 2;342(8875):821-8.
CIBIS II The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999 Jan 2;353 (9146):9-13.
MERIT HF Hjalmarson A, Goldstein S, Fagerberg B Effects of controlled- release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000 Mar 8;283(10):1295-302.
COPERNICUS Packer M, Coats AJ, Fowler MB Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001 May 31;344(22):1651-8.
RALES Pitt B, Zannad F, Remme, WJ The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999 Sep 2;341(10):709-17.
DIG The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997 Feb 20;336(8):525-33.
CHARM Granger CB , McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function and intolerant to ACE inhibitors: the CHARM-Alternative Trial. Lancet 2003;362:772-76
McMurray JJV, Östergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function treated with an ACE inhibitor: the CHARM-Added trial. Lancet 2003;362:767-71
Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left ventricular systolic function: the CHARM-Preserved Trial. Lancet 2003;362:777-81.
Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme. Lancet 2003;362:759-66
Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906.
EPHESUS Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N Engl J Med 2003;348:1309-21.
EMPHASIS-HF Zannad F, et al. Eplerenone in patients with systolic heart failure and mild symptoms. The New England Journal of Medicine. 2011. 364(1):11-21.
CONFIRM-HF B Piotr Ponikowski, Dirk J. van Veldhuisen. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency European Heart Journal, Aug 2014,DOI: 10.1093/eurheartj/ehu385
PARADIGM-HF John J.V., McMurray, M.D., Milton Packer N Engl J Med 2014;371:993-1004 September 11, 2014DOI:10.1056/NEJMoa1409077
DAPA-HF McMurray et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019; 381:1995-2008
EMPEROR-Reduced Milton Packer et al.Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020; 383:1413-1424
M.A. Pfeffer, B. Claggett, E.F. Lewis et al. Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction. N Engl J Med 2021;385:1845-55.
TRANSITION Rolf Wachter, Michele Senni, Jan Belohlavek et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge. European Journal of Heart Failure (2019) 21, 998–1007. Eric J. Velazquez, David A. Morrow, Adam D. DeVore et al. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med Volume 380(6):539-548,February 7, 2019
PARADISE MI M.A. Pfeffer, B. Claggett, E.F. Lewis et al. Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction. N Engl J Med 2021;385:1845-55.
PARAGON-HF Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction N Engl J Med 2019; 381:1609- 1620
2021 ECS Guidelines for the diagnosis and treatment of acute and chronic heart failure; European Heart Journal (2021) 42, 3599-3726
EMPULSE A. A. Voors et al., "The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial," (in eng), Nat Med, vol. 28, no. 3, pp. 568-574, Mar 2022, doi: 10.1038/s41591-021- 01659-1
DELIVER Scott D. Solomon, M.D.,Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction; N Engl J Med August 27, 2022 DOI: 10.1056/NEJMoa2206286
EMPEROR-Preserved Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al; Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021 Oct 14;385(16):1451-1461
